| scholarly article | Q13442814 |
| P2093 | author name string | Alice Chen | |
| James H Doroshow | |||
| Lee Helman | |||
| Robert Kinders | |||
| Seth M Steinberg | |||
| Melinda Hollingshead | |||
| Joseph E Tomaszewski | |||
| Anthony J Murgo | |||
| Martin Gutierrez | |||
| Shivaani Kummar | |||
| Jiuping Ji | |||
| Larry Rubinstein | |||
| Ralph E Parchment | |||
| Sherry X Yang | |||
| Jerry Collins | |||
| Robert Wiltrout | |||
| P2860 | cites work | Can the pharmaceutical industry reduce attrition rates? | Q29616077 |
| Receptor imaging in oncology by means of nuclear medicine: current status | Q35874804 | ||
| The progress and promise of molecular imaging probes in oncologic drug development | Q36318111 | ||
| Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials | Q36622291 | ||
| Innovative early development regulatory approaches: expIND, expCTA, microdosing | Q37037370 | ||
| Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice | Q37058731 | ||
| The development of phase I cancer trial methodologies: the use of pharmacokinetic and pharmacodynamic end points sets the scene for phase 0 cancer clinical trials | Q37193276 | ||
| Phase 0 trials: an industry perspective | Q37193278 | ||
| Imaging and other biomarkers in early clinical studies: one step at a time or re-engineering drug development? | Q46607034 | ||
| Phase 0 trials: are they ethically challenged? | Q53205998 | ||
| Compressing drug development timelines in oncology using phase '0' trials | Q53208031 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 3675-3682 | |
| P577 | publication date | 2008-06-01 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Designing phase 0 cancer clinical trials | |
| P478 | volume | 14 |
| Q95851906 | A Review on: Phase '0' Clinical Trials or Exploratory Investigational New Drug |
| Q37552670 | Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee |
| Q38843584 | Bioactivity of Oral Linaclotide in Human Colorectum for Cancer Chemoprevention |
| Q52151988 | Brain Tumor Clinical Trials: Perspective 2014. |
| Q92065355 | Clinical Trials in Alzheimer's Disease: A Hurdle in the Path of Remedy |
| Q57266579 | Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2 |
| Q34316288 | Development of a validated immunofluorescence assay for γH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity |
| Q39842254 | Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor |
| Q37845248 | Drug therapy of cancer |
| Q45929421 | EORTC trial 11001: distribution of two 10B-compounds in patients with squamous cell carcinoma of head and neck, a translational research/phase 1 trial. |
| Q36853927 | Early-Phase Development of Cancer Prevention Agents: Challenges and Opportunities |
| Q39010445 | FGFR-TACC gene fusions in human glioma |
| Q37859450 | Health technology assessment in the era of personalized health care |
| Q50422614 | Molecular Pharmacodynamics-Guided Scheduling of Biologically Effective Doses: A Drug Development Paradigm Applied to MET Tyrosine Kinase Inhibitors. |
| Q36641721 | New considerations in the design of clinical trials for the treatment of acute leukemia |
| Q37458170 | Next generation oncology drug development: opportunities and challenges |
| Q36137870 | Normal tissue protection for improving radiotherapy: Where are the Gaps? |
| Q36732058 | Oncologic phase 0 trials incorporating clinical pharmacodynamics: from concept to patient |
| Q38818203 | Pharmacodynamic endpoints as clinical trial objectives to answer important questions in oncology drug development |
| Q34701702 | Phase 0 Clinical Chemoprevention Trial of the Akt Inhibitor SR13668 |
| Q93068407 | Phase 0 Clinical Trial Strategies for the Neurosurgical Oncologist |
| Q35602195 | Phase 0 Workshop at the 20th EORTC-NCI-AACR Symposium, Geneva. |
| Q37358487 | Phase 0 clinical studies in oncology |
| Q37337123 | Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies |
| Q34941964 | Phase 0 clinical trials in oncology new drug development |
| Q33985780 | Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies |
| Q35883053 | Phase 0 clinical trials: towards a more complete ethics critique |
| Q84400479 | Phase 0 exploratory clinical trials: literature review 2006-2009 |
| Q34802510 | Phase 0 trials: expediting the development of chemoprevention agents |
| Q38119561 | Phase zero trials: a novel approach in drug development process |
| Q28537857 | Proof of the concept to use a malignant B cell line drug screen strategy for identification and weight of melphalan resistance genes in multiple myeloma |
| Q57112620 | Prostate cancer chemoprevention by natural agents: Clinical evidence and potential implications |
| Q26824597 | Selecting the Best Drugs for Phase I Clinical Development and Beyond |
| Q47217032 | State of the Science: Cancer Complementary and Alternative Medicine Therapeutics Research-NCI Strategic Workshop Highlights of Discussion Report |
| Q86365566 | Technological challenges of theranostics in oncology |
| Q37515513 | The statistics of phase 0 trials |
| Q44124550 | Timely Completion of Scientifically Rigorous Cancer Clinical Trials: An Unfulfilled Priority |
| Q39044141 | Toward Personalized Targeted Therapeutics: An Overview |
| Q37602380 | Translational research in phase I trials |
| Q28073826 | Unveiling changes in the landscape of patient populations in cancer early drug development |
| Q38092552 | Using viral-mediated gene delivery to model Parkinson's disease: Do nonhuman primate investigations expand our understanding? |
| Q46597773 | Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements |
| Q33775647 | What are the endpoints of therapy for acute leukemias? Old definitions and new challenges |
Search more.